Zacks Investment Research downgraded shares of Checkpoint Therapeutics (NASDAQ:CKPT) from a buy rating to a hold rating in a research note published on Wednesday.
According to Zacks, “Checkpoint Therapeutics, Inc. is a clinical stage, immuno oncology biopharmaceutical. It focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Checkpoint Therapeutics, Inc. is headquartered in New York City. “
Separately, HC Wainwright assumed coverage on shares of Checkpoint Therapeutics in a report on Friday, December 8th. They set a buy rating and a $11.00 price objective for the company.
Checkpoint Therapeutics (CKPT) traded down $0.37 during midday trading on Wednesday, hitting $3.24. 102,700 shares of the stock were exchanged, compared to its average volume of 91,767. Checkpoint Therapeutics has a 52 week low of $3.20 and a 52 week high of $15.00. The company has a market cap of $91.26 and a P/E ratio of -2.89.
TRADEMARK VIOLATION NOTICE: “Checkpoint Therapeutics (CKPT) Lowered to Hold at Zacks Investment Research” was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://transcriptdaily.com/2018/01/05/checkpoint-therapeutics-ckpt-lowered-to-hold-at-zacks-investment-research.html.
Checkpoint Therapeutics Company Profile
Checkpoint Therapeutics, Inc is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies.
Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.